ModifiedPremera BluecrossPolicy 2.01.533

Upper Gastrointestinal (UGI) Endoscopy in Adults

Customize your policy alerts

Sign up for Premera Bluecross Policy 2.01.533 alerts

Get alerted when Policy 2.01.533 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical necessity and site-of-service coverage criteria for upper gastrointestinal endoscopy (EGD/UGI) in adults (age 19+), including indications, documentation, and coding guidance for Premera Bluecross.

Policy Summary

PayerPremera Bluecross

PolicyUpper Gastrointestinal (UGI) Endoscopy in Adults

Policy CodePolicy 2.01.533

Change TypeTitle changeASC site-of-service criteriamultiple indication updates

Effective DateSep 1, 2026

Last ReviewAug 1, 2026

Next Review DateSep 1, 2026

Key ActionDocument an 8-week continuous daily PPI trial (or contraindication) and relevant alarm symptoms when requesting prior authorization for EGD.

SourceLink

POLICY UPDATE CHANGES

Changed policy title from 'for Adults' to 'In Adults' and added ASC Site of Service review criteria (does not apply to IHS facilities).

Removed criterion for UGI performed for evaluation of the return of GERD or dyspepsia symptoms after PPI therapy has been discontinued.

Modified UGI indication for pernicious anemia to specify 'Individuals with newly diagnosed (within one year) pernicious anemia.'

Added statement that UGI is considered not medically necessary for confirming Helicobacter pylori eradication.

Added that therapeutic banding (ligation) or sclerotherapy of esophageal varices is medically necessary.

19+Applies to individuals aged

3 months

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedPremera BluecrossPolicy 2.01.533

Upper Gastrointestinal (UGI) Endoscopy in Adults

Customize your policy alerts

Sign up for Premera Bluecross Policy 2.01.533 alerts

Get alerted when Policy 2.01.533 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerPremera Bluecross

PolicyUpper Gastrointestinal (UGI) Endoscopy in Adults

Policy CodePolicy 2.01.533

Change TypeTitle changeASC site-of-service criteriamultiple indication updates

Effective DateSep 1, 2026

Last ReviewAug 1, 2026

Next Review DateSep 1, 2026

Key ActionDocument an 8-week continuous daily PPI trial (or contraindication) and relevant alarm symptoms when requesting prior authorization for EGD.

SourceLink

POLICY UPDATE CHANGES

Changed policy title from 'for Adults' to 'In Adults' and added ASC Site of Service review criteria (does not apply to IHS facilities).

Removed criterion for UGI performed for evaluation of the return of GERD or dyspepsia symptoms after PPI therapy has been discontinued.

Modified UGI indication for pernicious anemia to specify 'Individuals with newly diagnosed (within one year) pernicious anemia.'

Added statement that UGI is considered not medically necessary for confirming Helicobacter pylori eradication.

Added that therapeutic banding (ligation) or sclerotherapy of esophageal varices is medically necessary.

19+Applies to individuals aged

3 months

Minimum GERD duration before endoscopy

8 weeksRequired PPI trial duration

3-5 yrsBarrett surveillance interval (no dysplasia)

43235-43242Example listed CPT codes

Coverage Criteria — When UGI Endoscopy Is Medically Necessary

Medically Necessary Indications

Covered when ANY of the following documented indications are present for individuals aged 19 and older:

Malignant or high-risk hereditary indications: Barrett esophagus, dysplasia, esophageal cancer, familial adenomatous polyposis (FAP), gastric cancer, head/neck cancer, Lynch syndrome or hereditary nonpolyposis, prior adenomatous or sessile polyps of the stomach/duodenum/esophagus, CDH1 mutation (one evaluation), family history of UGI cancer in a first-degree relative, or tylosis.

Alarm symptoms: Iron deficiency anemia; rectal or dark/bright red blood in stool; epigastric mass on exam; persistent vomiting including hematemesis; dysphagia; unintentional weight loss ≥3 kg since symptom onset.≥3 kg weight loss

Follow-up of known non-malignant conditions: Evaluation or treatment of suspected portal hypertension/cirrhosis (including variceal screening), follow-up of known eosinophilic or erosive esophagitis, therapeutic banding or sclerotherapy of esophageal varices (with post‑eradication surveillance), treatment of bleeding lesions (e.g., ulcers), history of gastric surgery, persistent symptoms after stopping NSAIDs, persistent non-cardiac chest pain, odynophagia, or dysphagia.

Variceal surveillance: 1–3 months after eradication, then every 6–12 months

GERD/Dyspepsia: Performed for GERD or dyspepsia symptoms present ≥3 months AND persistent despite 8 weeks of continuous daily proton pump inhibitor (PPI) therapy (H2RA acceptable only if PPI intolerant or contraindicated).≥3 months; 8 weeks PPI trial

Documentation of PPI trial required when applicable

Barrett esophagus surveillance intervals: High-grade dysplasia: repeat UGI every 3 months after initial biopsy for 1 year, then annually; Low-grade dysplasia: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter; No dysplasia (metaplasia): repeat one time within 12 months after initial biopsy then every 3 years if unchanged.

Other covered indications: Initial variceal screening at cirrhosis diagnosis (then no more frequently than annually), Crohn disease involving the UGI tract, caustic ingestion assessment, foreign body removal, confirmation and follow-up of gastric/peptic/esophageal ulcers when conservative management failed or is contraindicated (follow-up every 2 months until healed), pre-transplant evaluation, preoperative bariatric evaluation (unless bariatric excluded by contract), individuals with newly diagnosed (within 1 year) pernicious anemia, post-cardiac ablation evaluation, screening for Barrett in males ≥50 with ≥5 years GERD plus risk factors (e.g., BMI ≥30, nighttime reflux, tobacco use), assessment of diarrhea for suspected small-bowel disease, and evaluation of UGI obstruction/stricture.Pernicious anemia: within 1 year; Barrett screening: male ≥50 with ≥5 years GERD

Not Medically Necessary

Not medically necessary when ANY of the following apply:

Not medically necessary conditions: Evaluation of chronic, non‑progressive, functional UGI symptoms without red flags (except occasional one‑time exam to exclude organic disease when unresponsive to therapy); uncomplicated heartburn that responds to conservative management; endoscopy when results will not alter management; asymptomatic or uncomplicated radiographic findings (e.g., asymptomatic sliding hiatal hernia, deformed or uncomplicated duodenal bulb/responding duodenal ulcer); routine screening of the UGI tract in the absence of a clinical indication; surveillance of healed benign disease (e.g., gastric or duodenal ulcer); surveillance of gastric intestinal metaplasia; and UGI performed to confirm Helicobacter pylori eradication.

Medically necessary indications

Covered when meeting guideline‑indicated scenarios per referenced society recommendations

Alarm symptoms (guideline-based): EGD indicated for heartburn/GERD when any alarm symptom is present: anemia, bleeding, dysphagia, recurrent vomiting, or weight loss.

ACP Best Practice Advice 1

Refractory GERD after PPI trial: EGD indicated for typical GERD symptoms that persist despite a therapeutic trial of 4–8 weeks of twice‑daily PPI therapy or inadequate response to an 8‑week once‑daily PPI trial per ACG/ACP guidance.PPI trial: 4–8 weeks (BID) or 8 weeks (QD)

ACP Best Practice Advice 2; ACG recommendations (8‑week empiric PPI)

Dysphagia or odynophagia: EGD indicated for dysphagia or odynophagia to evaluate for structural or mucosal disease.

ASGE indications

Covered indications and guidance

Covered when indications are consistent with professional guidance and clinical need

Primary therapeutic/diagnostic indications: EGD is covered for active or recent GI bleeding; presumed chronic blood loss/iron deficiency anemia when an upper GI source is suspected or colonoscopy is negative; sampling of tissue or fluid when indicated; suspected portal hypertension to document or treat esophageal varices; assessment after caustic ingestion; treatment of bleeding lesions; banding or sclerotherapy of varices; removal of foreign bodies; resection of selected polypoid lesions; placement of feeding/drainage tubes; dilation of stenoses; management of achalasia; palliative treatment of stenosing neoplasms; endoscopic therapy of intestinal metaplasia; intraoperative evaluation of anatomic reconstructions; and management of operative adverse events.

Summarizes ASGE therapeutic and diagnostic uses

Surveillance EGD: Sequential or periodic EGD may be indicated for surveillance for malignancy in patients with premalignant conditions (for example, Barrett's esophagus) per referenced guidelines; surveillance frequency depends on the underlying premalignant condition and guideline recommendations.

ASGE/ACG guidance

GERD‑specific guidance: For GERD, EGD is recommended for patients with alarm symptoms (dysphagia, odynophagia, weight loss, GI bleeding, persistent vomiting, unexplained iron deficiency). For GERD without alarm symptoms, consider endoscopy in those with Barrett's risk factors (age ≥50, male sex, white race, smoking, obesity). Initial management should prioritize PPI therapy at the lowest effective dose; for suboptimal PPI responders consider testing for CYP2C19 polymorphism and adjusting therapy.

Notable coverage items from policy history

Selected notable coverage criteria and changes recorded in the history:

Therapeutic intervention: UGI considered medically necessary for treatment of bleeding lesions such as gastric, peptic, or esophageal ulcers; follow‑up UGI for such ulcers every 2 months until healed (history note added 2023).

added Apr/Feb 2023 per history entries

Barrett's esophagus surveillance: For low‑grade dysplasia: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter (history addition Mar 2024).

added Mar 2024

Esophageal varices: Therapeutic banding (ligation) or sclerotherapy of esophageal varices is medically necessary; surveillance schedule for esophageal varices clarified (history entries Sep 2022/Jan 2023).

added Sep 2022; clarified Jan 2023

Pernicious anemia:

This policy excludes endoscopic procedures performed as routine screening of the upper gastrointestinal (UGI) tract when there is no clinical indication. It also excludes sequential or periodic surveillance of healed benign disease (for example, healed gastric or duodenal ulcers) and surveillance of gastric intestinal metaplasia. Procedures performed when the endoscopy result will not alter management or to evaluate asymptomatic radiographic findings that have responded to therapy are likewise not covered.

Esophagogastroduodenoscopy (EGD) is generally not indicated for symptoms that are considered functional in origin unless there are red flags or an isolated, one-time exam is needed to exclude organic disease after failure of conservative therapy. The American Society for Gastrointestinal Endoscopy (ASGE) guidance notes exceptions for a single exam when symptoms are unresponsive to therapy, but routine endoscopy for functional symptoms is not supported.

An occasional single endoscopic examination may be reasonable to exclude organic disease when symptoms are persistent and unresponsive to therapy, but repeated or routine EGD solely for functional symptoms is not covered. The policy emphasizes that one-time diagnostic EGD for unexplained or refractory presentations may be appropriate, while ongoing surveillance without clinical change is not.

This medical policy is a guide for commercial business and does not apply to Medicare Advantage. Member contracts vary in benefits and limits; providers should consult the member benefit booklet or contact customer service to confirm coverage for a specific individual.

UGI endoscopy is considered not medically necessary when the documented clinical indications in this policy are not met. Examples include evaluation of chronic, non‑progressive functional UGI symptoms without alarm features, uncomplicated heartburn responsive to conservative management, routine screening in the absence of clinical indication, surveillance of healed benign disease, surveillance of gastric intestinal metaplasia, and procedures performed when results will not change clinical management.

When the service does not meet any of the policy’s covered indications—such as absence of alarm symptoms, lack of documented failed conservative therapy when required, or when endoscopy would not alter management—the procedure is a candidate for denial as not medically necessary. Providers should document clinical findings and prior conservative management to support medical necessity.

Sequential or periodic EGD for the purpose of surveillance of previously healed benign conditions (for example, healed esophagitis or gastric/duodenal ulcer) is generally not indicated and is considered not medically necessary unless there is a new clinical change or other covered indication.

Surveillance endoscopy is generally not indicated for several conditions where routine malignancy surveillance is not supported by evidence or guidelines—examples include gastric atrophy, pernicious anemia (except newly diagnosed cases specified elsewhere), fundic gland or hyperplastic polyps, and prior gastric operations for benign disease. Routine surveillance in these settings is considered not medically necessary.

Endoscopy performed solely to confirm eradication of Helicobacter pylori is considered not medically necessary. The policy explicitly states that UGI endoscopy should not be used for confirmation of H. pylori eradication.

UGI endoscopy performed for surveillance of individuals with gastric intestinal metaplasia is considered not medically necessary. This surveillance statement was added to the policy history and indicates that routine endoscopic surveillance for this condition is not covered absent another qualifying indication.

Coding and Billing Guidance

Covered CPT Codes (excerpt)CPTCovered

43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure).
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures).
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple.
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis).

Historical CPT code notesCPT

43270	CPT 43270 was added for 2014 (historical note)
43233-34, 43237	Informational CPT codes removed (historical note)
43252	CPT 43252 removed from policy in 2013 as it pertains to another policy (historical note)

Historical code notesCPT

43270	CPT code added in 2014 (informational reference in history)
43233-43234, 43237	Informational CPT codes removed in 2015 history notes

BMI — Risk thresholds referenced

Morbid obesity (site-of-service risk)BMI ≥ 50 is listed as an increased risk factor for site-of-service review (morbid obesity).

Barrett screening — male age thresholdScreening for Barrett esophagus is indicated in male individuals aged ≥50 with ≥5 years of GERD symptoms when 1 or more risk factors present, including BMI ≥ 30 kg/m².

BMI threshold referenced for Barrett riskBMI ≥ 30 kg/m² cited as an elevated BMI risk factor for Barrett esophagus screening in males ≥50.

Barrett's esophagus surveillance intervals

Low-grade dysplasia (LGD)Repeat UGI at 6 months, then surveillance at 12 months and annually thereafter.

Provider Actions — Prior Authorization, Documentation, and Denial Risks

Prior Authorization

Site-of-service review required for elective UGI procedures

Elective diagnostic or surgical UGI procedures will be reviewed for medical necessity and for the most appropriate site of service; ambulatory surgical center (ASC) is the preferred medically necessary site when available, with hospital outpatient acceptable only when ASC access is unavailable or the patient has specified increased risk factors (examples: morbid obesity BMI ≥50, significant cardiopulmonary, liver, renal, anesthesia or other risks, pregnancy).

Preferred medically necessary sites: Ambulatory surgical center; off‑campus outpatient hospital/medical center; on‑campus outpatient hospital/medical center.
Hospital outpatient may be necessary when no qualifying ASC within 30 miles, no ASC with required equipment or physician privileges, or ASC guidelines prohibit use for patient’s condition/weight.
Examples of increased risk factors that may warrant hospital site: ASA III+, morbid obesity (BMI ≥50), advanced liver disease (MELD >8), severe COPD/OSA, recent MI/CVA, ESRD on dialysis, pregnancy.

Prior Authorization

Prior authorization must show therapy trial and alarm symptom evaluation

Background — Clinical Context

Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) inspects the esophagus, stomach, and duodenum using a flexible endoscope. It is used to evaluate causes of severe or persistent heartburn, dysphagia, persistent vomiting, gastrointestinal bleeding, and to perform therapeutic interventions such as variceal banding, biopsy, dilation, foreign body removal, or feeding tube placement.

Definitions and Terms

Barrett esophagus — definition and risk summary

DefinitionBarrett esophagus: replacement of normal esophageal squamous epithelium by metaplastic columnar or glandular epithelium associated with GERD and increased risk of esophageal adenocarcinoma.

Association with GERDPolicy notes Barrett esophagus arises after GERD damages the esophageal epithelium and predisposes to adenocarcinoma.

Surveillance importanceBarrett esophagus is specifically included in covered indications and has defined surveillance intervals stratified by dysplasia (no dysplasia, low-grade, high-grade).

Esophagogastroduodenoscopy (EGD) — definition

TermEsophagogastroduodenoscopy (EGD): term used in place of upper gastrointestinal endoscopy for diagnostic/therapeutic examination of the esophagus, stomach, and duodenum.

Use

Revision History and Policy Changes

2026-08-01Interim ReviewLatest

Interim review approved July 14, 2026; removed criterion for UGI to evaluate return of GERD/dyspepsia after PPI discontinuation and updated ASGE Practice and Position statement.

2026-06-16Effective date change

Policy effective date moved from July 1, 2026 to September 1, 2026 due to operational readiness.

2026-03-27Effective date change

Policy Summary

PayerPremera Bluecross

PolicyUpper Gastrointestinal (UGI) Endoscopy in Adults

Policy CodePolicy 2.01.533

Change TypeTitle changeASC site-of-service criteriamultiple indication updates

Effective DateSep 1, 2026

Last ReviewAug 1, 2026

Next Review DateSep 1, 2026

Key ActionDocument an 8-week continuous daily PPI trial (or contraindication) and relevant alarm symptoms when requesting prior authorization for EGD.

SourceLink

On This Page

Non‑cardiac chest pain: In patients with chest pain after cardiac causes are excluded, objective testing for GERD (endoscopy and/or reflux monitoring) is recommended.

ACG conditional recommendation

Barrett esophagus surveillance (guideline stratified): Surveillance endoscopy recommended with intervals stratified by dysplasia: no dysplasia every 3–5 years; low‑grade dysplasia surveillance at ~12 months (or endoscopic therapy); high‑grade dysplasia should receive endoscopic therapy.No dysplasia: 3–5 years; Low‑grade: ~12 months; High‑grade: therapy recommended

ACG and taskforce guidance

Other ASGE indications: EGD indicated for persistent upper abdominal symptoms despite therapy, suspected neoplastic lesions, gastric/esophageal ulcer, upper GI bleeding, sampling for tissue/fluid, suspected portal hypertension, caustic ingestion assessment, foreign body removal, therapeutic interventions (dilation, variceal therapy, polypectomy, feeding tube placement), and management of operative adverse events.

ASGE standards of practice

Reflects ASGE 2025 guideline summary included in policy

UGI modified to be medically necessary for individuals with newly diagnosed (within one year) pernicious anemia (interim review Jan 2026).

Interim review Jan 2026

H. pylori eradication: UGI is considered not medically necessary for confirming Helicobacter pylori eradication (added Sep 2025).

added Sep 2025

No dysplasia (metaplasia)

Repeat UGI one time within 12 months after initial biopsy; then every 3 years if pathology unchanged (policy text).

High-grade dysplasia (HGD)Repeat UGI every 3 months after initial biopsy for 1 year, then annually (as surveillance schedule for HGD).

Prior authorization requests must document that recommended conservative therapy trials and evaluation for alarm symptoms were performed before approval for diagnostic EGD (for example, an 8‑week trial of continuous daily PPI for classic GERD symptoms or documentation of alarm features).

Document an empiric 8‑week once‑daily PPI trial for classic GERD symptoms when no alarm features are present (ACG recommendation).
Record presence or absence of alarm symptoms (anemia, bleeding, dysphagia, recurrent vomiting, weight loss) as part of the authorization submission.

Prior Authorization

Prior authorization: medical necessity must be documented

Prior authorization must include documentation supporting medical necessity per this policy and relevant guidelines; endoscopic procedures are covered when reasonable and necessary for the individual patient.

Provide clinical rationale referencing covered indications (e.g., active GI bleeding, suspected upper GI source of iron deficiency anemia, therapeutic needs).

Prior Authorization

Follow site‑of‑service and prior authorization processes (ASC criteria added)

ASC site‑of‑service review criteria were added; follow utilization management and prior authorization processes for both site‑of‑service determination and procedure coverage (ASC preferred when criteria met; IHS facilities exempt).

ASC preference applies to select elective diagnostic/surgical procedures; consult utilization management when ASC access or patient risk factors affect site selection.
Site‑of‑service review does not apply to Indian Health Services (IHS) facilities.

Step Therapy

Require 8 weeks continuous daily PPI before endoscopy for GERD/dyspepsia

For GERD or dyspepsia indications, clinical documentation should show an 8‑week trial of continuous daily PPI therapy prior to endoscopy unless the PPI is contraindicated or not tolerated (H2RA acceptable only if PPI intolerance/contraindication).

If PPI intolerance/contraindication, a standard‑dose H2RA may substitute as documented (per Table 1).
Record duration and dosing of PPI therapy in the clinical note submitted with the authorization request.

Step Therapy

Step therapy: empiric 8‑week PPI trial required before diagnostic EGD

Step therapy requires an empiric antisecretory medication trial—standard PPI dosing for approximately 8 weeks—before proceeding to diagnostic endoscopy in patients without alarm features.

Document PPI drug, dose, start and end dates, and response to therapy in the prior authorization submission.
If symptoms persist despite an appropriate PPI trial, include this information and any adjustments (e.g., twice‑daily dosing per ACG/ASGE recommendations) where applicable.

Step Therapy

Emphasize guideline‑recommended medical management before EGD in GERD

Guideline‑recommended, stepwise medical management for GERD should be attempted prior to endoscopy in patients without alarm symptoms or Barrett risk factors; this includes an appropriate PPI trial and other medical measures as indicated.

Use an 8‑week once‑daily PPI trial for classic GERD symptoms without alarm features; consider further trials (e.g., 4–8 weeks twice‑daily) for refractory symptoms per guideline guidance.
Document non‑pharmacologic measures and any prior diagnostic testing as relevant.

Documentation Required

Document PPI therapy duration and prior treatment history

When submitting prior authorization or medical records, include PPI therapy duration and related prior treatment history (dates, doses, response), since prior policy revisions and the current policy reference specific PPI durations when evaluating necessity.

Include past therapy details (e.g., prior 8‑week PPI trials, changes in dosing, intolerance) in clinical notes to support the need for endoscopy.
Note any historical criteria changes only as context for documentation of prior therapy when relevant to the current request.

Documentation Required

Required clinical documentation: malignant, alarm, or high‑risk indications

Clinical notes must document malignant indications, alarm symptoms, or high‑risk non‑malignant conditions needing follow‑up/treatment to support medical necessity for UGI endoscopy.

Examples to document: active or recent GI bleeding, suspected portal hypertension/cirrhosis, eosinophilic esophagitis, erosive esophagitis, dysphagia/odynophagia, variceal disease, or history of gastric surgery.
Include objective findings or prior test results that prompted the request (e.g., positive fecal blood, iron deficiency anemia workup).

Documentation Required

Document trial and duration of medical therapy and alarm symptoms

Document the trial and exact duration of medical therapy (e.g., an 8‑week continuous daily PPI trial when indicated) and the presence or absence of alarm symptoms (anemia, bleeding, dysphagia, recurrent vomiting, weight loss) in the clinical record submitted for authorization.

Specify medication name, dose, dates of use, and clinical response.
Explicitly state whether alarm symptoms are present; if absent, document that conservative management was attempted and failed or was inadequate.

Documentation Required

Clinical indication documentation: support for GI bleeding or chronic blood loss

When anemia or suspected chronic blood loss is the indication, documentation should support active or recent GI bleeding or that an upper GI source is suspected (for example, colonoscopy was negative), to justify EGD.

Include hemoglobin/iron studies, fecal blood testing, colonoscopy results if available, and clinical rationale for suspecting an upper GI source.

Documentation Required

Provide supporting documentation for medical necessity

Provide supporting medical records and documentation as required by the policy’s Documentation Requirements section (added March 2018) to substantiate medical necessity for the requested procedure.

Submit clinical notes, prior test results, medication trial details, and any specialist consultations that support the indication.
Ensure documentation aligns with member benefit plan limits and the policy’s criteria.

Denial Risk

Denial triggers: common reasons for non‑coverage

UGI endoscopy will be denied (not medically necessary) when policy criteria are not met — common triggers include performing endoscopy for functional symptoms without red flags, routine surveillance of healed benign disease, or for indications that will not alter management (including confirming H. pylori eradication).

Do not submit authorization for chronic, non‑progressive functional UGI symptoms without alarm features unless a one‑time exam is clearly warranted.
Requests to confirm H. pylori eradication or for routine surveillance of healed benign disease are listed as not medically necessary.

Denial Risk

Denial risk if conservative medical management not tried first

Performing EGD without prior conservative medical management (for example, skipping an appropriate PPI trial in GERD/dyspepsia when no alarm features are present) risks denial because professional societies recommend conservative management first in the absence of suspected cancer.

When no clear cancer diagnosis or alarm features exist, document an empiric PPI trial and other conservative measures before requesting invasive diagnostic testing.

Denial Risk

Common triggers for non‑coverage or denial risk

Common triggers for non‑coverage or denial include requests for endoscopy for symptoms considered functional in origin, procedures unlikely to change management (e.g., metastatic adenocarcinoma of unknown primary when results won’t alter care), and certain asymptomatic radiographic findings.

Examples: asymptomatic sliding hiatal hernia, uncomplicated duodenal ulcer that responded to therapy, deformed duodenal bulb when asymptomatic.
Surveillance for conditions not supported by guidance (e.g., routine surveillance for gastric intestinal metaplasia) may also be non‑covered.

Note

Benefit limitations may trigger denial — verify member benefits

Consult the member benefit booklet or contact customer service before scheduling procedures because coverage determinations are subject to member plan limits, exclusions, and benefit limitations that may trigger denial.

Member contracts differ; verify benefits and any plan‑specific limitations prior to submitting authorization or performing the procedure.

EGD is used to inspect and sample tissue, treat bleeding lesions, remove foreign bodies, dilate strictures, place feeding tubes, and perform other therapeutic interventions.

Gastroesophageal reflux disease (GERD) — definition

DefinitionGastroesophageal reflux disease (GERD): a chronic disorder of the lower esophageal sphincter where stomach contents flow back into the esophagus causing symptoms such as heartburn, regurgitation, and noncardiac chest pain.

Clinical contextGERD is a common underlying condition referenced throughout the policy as an indication for EGD when alarm features or risk factors for Barrett are present.

Odynophagia — definition

DefinitionOdynophagia: the sensation of burning or squeezing pain when swallowing.

RelevanceListed as an alarm symptom warranting EGD to evaluate for structural or mucosal disease.

Medical management — definition

DefinitionMedical management: non-invasive interventions such as acid suppressive medications, dietary/nutritional counseling, weight loss counseling, and environmental changes (e.g., head-of-bed elevation).

Prior therapy requirementPolicy requires documentation of appropriate medical management (e.g., an 8-week continuous daily PPI trial for GERD/dyspepsia) before EGD when indicated and no alarm features are present.

Tylosis — definition

DefinitionTylosis: a rare autosomal dominant syndrome causing focal palm/sole hyperkeratosis and associated with increased risk of esophageal squamous cell carcinoma.

Clinical noteIncluded among high-risk hereditary indications for which EGD may be medically necessary.

Therapeutic EGD indications — definition

DefinitionTherapeutic EGD indications: procedures performed during EGD to treat disease, such as treatment of bleeding lesions (electrocoagulation, heater probe, injection), banding/sclerotherapy of varices, removal of foreign bodies, polypectomy, feeding/drainage tube placement, dilation of stenoses, management of achalasia, stent placement, and endoscopic therapy of intestinal metaplasia.

Policy implicationTherapeutic indications are listed among covered indications where EGD is medically necessary for treatment rather than diagnostic evaluation.

Non-indicated uses — definition

DefinitionNon-indicated uses: evaluations generally not indicated include endoscopy for symptoms considered functional in origin (absent red flags), metastatic adenocarcinoma of unknown primary when results will not alter management, and certain asymptomatic radiographic findings (e.g., asymptomatic sliding hiatal hernia, uncomplicated duodenal ulcer that responded to therapy).

Surveillance caveatSequential or periodic EGD generally not indicated for surveillance of healed benign disease or for premalignant gastric conditions where routine surveillance is unsupported.

Adult — definition

DefinitionAdult: patients 19 years of age and older as defined in the policy and prior revisions.

Scope notePolicy statements and criteria apply only to individuals aged 19 and older unless otherwise specified.

Scope (non-Medicare Advantage)

DefinitionScope (non-Medicare Advantage): this medical policy does not apply to Medicare Advantage; member contracts and benefit limits differ and should be consulted.

Provider actionProviders and members should consult the member benefit booklet or contact customer service to determine coverage for Medicare Advantage plans or specific benefit limits.

Policy effective date updated from May 1, 2026 to July 1, 2026 due to operational readiness.

2026-02-24Effective date change

Policy effective date updated from March 4, 2026 to May 1, 2026 due to a business decision based on operational readiness.

2026-02-01Interim Review

Interim review approved January 13, 2026; modified UGI indication for pernicious anemia to specify individuals with newly diagnosed (within one year) pernicious anemia.

2025-09-01Annual Review / Addition

Annual review approved August 12, 2025; added statement that UGI is not medically necessary for confirming Helicobacter pylori eradication and other clarifications.

2024-05-01Annual Review / Addition

Interim review approved February 12, 2024 and annual review approved April 9, 2024; added Barrett esophagus low-grade dysplasia surveillance schedule (repeat at 6 months, then 12 months and annually thereafter).

2023-10-01Annual Review

Interim review approved January 10, 2023 and subsequent updates in 2023 clarified surveillance statements and added that UGI for surveillance of healed benign disease is not medically necessary.

2022-09-01Interim Review

Interim reviews approved August 9 and December 13, 2022; added therapeutic banding/sclerotherapy of esophageal varices as medically necessary and other updates effective September 2, 2022.

2015-05-12Annual Review / Code changes

Annual review updated with literature through April 2015; added esophageal varices and cirrhosis to indications and removed informational CPT codes 43233-34 and 43237.

2014-12-22Interim Update

Interim update reclassified and renumbered policy (to 2.01.533) and moved from UM to Medicine section; 43270 added for 2014 in history notes.

2014Code addition (historical)

CPT code 43270 noted as added for 2014 in the policy history (informational).

2015Code removal (historical)

Informational CPT codes 43233-43234 and 43237 were removed from the policy history notes (not affecting adjudication).

2013Code removal (historical)

CPT 43252 was removed from the policy in 2013 as it pertains to another policy (historical note).

2014Historical code note

History records inclusion of CPT 43270 for 2014 as an informational entry.

2015Historical code note

History notes removal of informational CPT codes 43233-43234 and 43237 in 2015 history entries.